News

Aussie pharma on the nose

 Posted 1 May, 2026 AM

Australian pharma's corporate reputation is going downhill. The industry's approval rating among patient groups fell nine percentage points between 2024 and 2025, according to the latest PatientView survey – one of the worst results of the 37 countries and territories surveyed.

Fifty-five per cent of respondent patient groups in The Corporate Reputation of Pharma survey 2025-26 rated Australian pharma as having an ‘excellent’ or ‘good’ corporate reputation in 2025. Other countries and territories whose reputations slipped included Hong Kong (down 20 percentage points to a 60 per cent approval rating), Finland (down 19 points to 33 per cent) and the US (down eight points to 53 per cent).

To see the whole article, please login